Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival

Manuel Gentiluomo, Chiara Corradi, Giuseppe Vanella, Astrid Z. Johansen, Oliver Strobel, Andrea Szentesi, Anna Caterina Milanetto, Péter Hegyi, Juozas Kupcinskas, Francesca Tavano, John P. Neoptolemos, Dania Bozzato, Thilo Hackert, Raffaele Pezzilli, Julia S. Johansen, Eithne Costello, Beatrice Mohelnikova-Duchonova, Casper H.J. van Eijck, Renata Talar-Wojnarowska, Carsten Palnæs HansenErika Darvasi, Inna M. Chen, Giulia Martina Cavestro, Pavel Soucek, Liliana Piredda, Pavel Vodicka, Maria Gazouli, Paolo Giorgio Arcidiacono, Federico Canzian, Daniele Campa*, Gabriele Capurso

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)


Although pancreatic ductal adenocarcinoma (PDAC) survival is poor, there are differences in patients’ response to the treatments. Detection of predictive biomarkers explaining these differences is of the utmost importance. In a recent study two genetic markers (CD44-rs353630 and CHI3L2-rs684559) were reported to be associated with survival after PDAC resection. We attempted to replicate the associations in 1856 PDAC patients (685 resected with stage I/II) from the PANcreatic Disease ReseArch (PANDoRA) consortium. We also analysed the combined effect of the two genotypes in order to compare our results with what was previously reported. Additional stratified analyses considering TNM stage of the disease and whether the patients received surgery were also performed. We observed no statistically significant associations, except for the heterozygous carriers of CD44-rs353630, who were associated with worse OS (HR = 5.01; 95% CI 1.58–15.88; p = 0.006) among patients with stage I disease. This association is in the opposite direction of those reported previously, suggesting that data obtained in such small subgroups are hardly replicable and should be considered cautiously. The two polymorphisms combined did not show any statistically significant association. Our results suggest that the effect of CD44-rs353630 and CHI3L2-rs684559 cannot be generalized to all PDAC patients.

Original languageEnglish
Article number7570
JournalScientific Reports
Issue number1
Publication statusPublished - 7 Apr 2021

Bibliographical note

Funding Information:
This work was partially supported by: [D.C.; F.C.] intramural funds of Univerity of Pisa and DKFZ; [D.C.] Fon-dazione Tizzi (; [D.C.] Fondazione Arpa (; [B.M.D.] Ministry of Health of Czech Republic, NV 19–03-00097; [L.P.] Associazione Italiana Ricerca sul Cancro (AIRC 5 × 1000 n 12182); [P.S.] Czech Ministry of Health, project no. NV19-08–00113; [G.C.] Associazione Italiana Ricerca sul Cancro (AIRC IG IG 17177); [Division of Gastroenterology, Fondazione “Casa Sollievo della Sofferenza” IRCCS Hospital] Italian Ministry of Health (RC1803GA32) and the “5×1000” voluntary contribution.

Publisher Copyright:
© 2021, The Author(s).


Dive into the research topics of 'Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival'. Together they form a unique fingerprint.

Cite this